Home
About
Overview
Sharing Data
ORCID
Help
History (5)
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer.
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
Liposarcoma, Myxoid
Neuropathogenesis of delirium.
Risk factors of bronchial dehiscence after primary lung transplantation.
See All 5 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. Eur J Cancer. 2020 05; 130:155-167.
View in:
PubMed
subject areas
Aged
Antibodies, Monoclonal, Humanized
Carcinoma, Non-Small-Cell Lung
Female
Humans
Lung Neoplasms
Male
Programmed Cell Death 1 Receptor
Retrospective Studies
authors with profiles
Marina Chiara Garassino